Document 0593
 DOCN  M9440593
 TI    Primary in vitro sensitization of human T-helper lymphocytes by peptides
       derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1)
       envelope glycoprotein.
 DT    9404
 AU    Billaud JN; Yagello M; Gluckman JC; CNRS URA 1463, CERVI, Hopital de la
       Pitie-Salpetriere, Paris,; France.
 SO    Vaccine. 1994 Jan;12(1):46-55. Unique Identifier : AIDSLINE MED/94136014
 AB    To generate CD4+ T-helper cell lines, lymphocytes from HIV-seronegative
       subjects were primed in vitro with peptides derived from the V3 loop of
       HIV-1 gp120. Antigen-specific reactivity was inhibited by an anti-DR
       monoclonal antibody, indicating HLA-class II dependency, but peptides
       could be recognized in different HLA-class II contexts. Three sites on
       V3LAI and two on V3MN were identified as targets of the respective
       V3LAI- and V3MN-specific lines. Recognition of V3 peptides was
       isolate-specific. The lines did not react against whole gp160, which
       suggests that V3 may be differently presented when used as such rather
       than as part of the entire glycoprotein. Similar results were obtained
       in chimpanzees immunized in vivo against V3LAI.
 DE    Amino Acid Sequence  Animal  Antigen-Presenting Cells/IMMUNOLOGY  Cell
       Line  Chimpansee troglodytes  Flow Cytometry  Histocompatibility
       Antigens Class II  Human  HIV Envelope Protein gp120/*IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Leukocytes, Mononuclear/IMMUNOLOGY  Lymphocyte
       Transformation  Molecular Sequence Data  Peptide Fragments/*IMMUNOLOGY
       Support, Non-U.S. Gov't  T-Lymphocytes, Helper-Inducer/*IMMUNOLOGY
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).